MORGAN STANLEY PLC/PUT/ELI LILLY & CO/600/0.01/20.12.24 | Market Closed - Börse Stuttgart 02:51:11 2024-07-11 pm EDT | ||
| 0.045 EUR | +2.27% |
|
| Current month | -4.35% | ||
| 1 month | -27.87% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 0.045 | +2.27% |
| 24-07-10 | 0.044 | +2.33% |
| 24-07-09 | 0.043 | -8.51% |
| 24-07-08 | 0.047 | -4.08% |
| 24-07-05 | 0.049 | -15.52% |
Delayed Quote Börse Stuttgart
Last update July 11, 2024 at 02:51 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Morgan Stanley |
| WKN | ME0HJZ |
| ISIN | DE000ME0HJZ2 |
| Date issued | 2023-09-11 |
| Strike | 600 $ |
| Maturity | 2024-12-20 (162 Days) |
| Parity | 100 : 1 |
| Emission price | 0.81 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.01 € |
|---|---|
| Lowest since issue | 0.043 € |
| Spread | 0.008 € |
| Spread % | 15.09% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
939.8
USD
Average target price
887.2
USD
Spread / Average Target
-5.60%
- Stock Market
- Warrants
- Warrant
